Sphingosylphosphorylcholine ameliorates experimental sjögren's syndrome by regulating salivary gland inflammation and hypofunction, and regulatory B cells

Da Som Kim; Hyun Sik Na; Keun Hyung Cho; Kun Hee Lee; Jeong Won Choi; Seung Ki Kwok; Yoe Sik Bae; Mi La Cho; Sung Hwan Park

doi:10.1016/j.imlet.2022.06.008

Sphingosylphosphorylcholine ameliorates experimental sjögren's syndrome by regulating salivary gland inflammation and hypofunction, and regulatory B cells

Da Som Kim
, Hyun Sik Na
, Keun Hyung Cho
, Kun Hee Lee
, Jeong Won Choi
, Seung Ki Kwok
, Yoe Sik Bae
, Mi La Cho
, Sung Hwan Park

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Sjögren syndrome (SS) is an autoimmune disease in which immune cells infiltrate the exocrine gland. Since SS is caused by a disorder of the immune system, treatments should regulate the immune response. Sphingosylphosphorylcholine (SPC) is a sphingolipid that mediates cellular signaling. In immune cells, SPC has several immunomodulatory functions. Accordingly, this study verifies the immunomodulatory ability and therapeutic effect of SPC in SS. To understand the function of SPC in SS, we treated SPC in female NOD/ShiJcl (NOD) mice. The mice were monitored for 10 weeks, and inflammation in the salivary glands was checked. After SPC treatment, we detected the expression of regulatory B (B_reg) cells in mouse splenocytes and the level of salivary secretion-related genes in human submandibular gland (HSG) cells. Salivary flow rate was maintained in the SPC-treated group compared to the vehicle-treated group, and inflammation in the salivary gland tissues was relieved by SPC. SPC treatment in mouse cells and HSG cells enhanced B_reg cells and salivary secretion markers, respectively. This study revealed that SPC can be considered as a new therapeutic agent against SS.

Original language	English
Pages (from-to)	62-69
Number of pages	8
Journal	Immunology Letters
Volume	248
DOIs	https://doi.org/10.1016/j.imlet.2022.06.008
State	Published - Aug 2022

Bibliographical note

Publisher Copyright:
© 2022

Keywords

Regulatory B cells
Sjögren syndrome
Sphingosylphosphorylcholine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.imlet.2022.06.008

Cite this

@article{c9ca7515d67647a4b1029859c49ea798,

title = "Sphingosylphosphorylcholine ameliorates experimental sj{\"o}gren's syndrome by regulating salivary gland inflammation and hypofunction, and regulatory B cells",

abstract = "Sj{\"o}gren syndrome (SS) is an autoimmune disease in which immune cells infiltrate the exocrine gland. Since SS is caused by a disorder of the immune system, treatments should regulate the immune response. Sphingosylphosphorylcholine (SPC) is a sphingolipid that mediates cellular signaling. In immune cells, SPC has several immunomodulatory functions. Accordingly, this study verifies the immunomodulatory ability and therapeutic effect of SPC in SS. To understand the function of SPC in SS, we treated SPC in female NOD/ShiJcl (NOD) mice. The mice were monitored for 10 weeks, and inflammation in the salivary glands was checked. After SPC treatment, we detected the expression of regulatory B (Breg) cells in mouse splenocytes and the level of salivary secretion-related genes in human submandibular gland (HSG) cells. Salivary flow rate was maintained in the SPC-treated group compared to the vehicle-treated group, and inflammation in the salivary gland tissues was relieved by SPC. SPC treatment in mouse cells and HSG cells enhanced Breg cells and salivary secretion markers, respectively. This study revealed that SPC can be considered as a new therapeutic agent against SS.",

keywords = "Regulatory B cells, Sj{\"o}gren syndrome, Sphingosylphosphorylcholine",

author = "Kim, \{Da Som\} and Na, \{Hyun Sik\} and Cho, \{Keun Hyung\} and Lee, \{Kun Hee\} and Choi, \{Jeong Won\} and Kwok, \{Seung Ki\} and Bae, \{Yoe Sik\} and Cho, \{Mi La\} and Park, \{Sung Hwan\}",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = aug,

doi = "10.1016/j.imlet.2022.06.008",

language = "English",

volume = "248",

pages = "62--69",

journal = "Immunology Letters",

issn = "0165-2478",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Sphingosylphosphorylcholine ameliorates experimental sjögren's syndrome by regulating salivary gland inflammation and hypofunction, and regulatory B cells

AU - Kim, Da Som

AU - Na, Hyun Sik

AU - Cho, Keun Hyung

AU - Lee, Kun Hee

AU - Choi, Jeong Won

AU - Kwok, Seung Ki

AU - Bae, Yoe Sik

AU - Cho, Mi La

AU - Park, Sung Hwan

PY - 2022/8

Y1 - 2022/8

N2 - Sjögren syndrome (SS) is an autoimmune disease in which immune cells infiltrate the exocrine gland. Since SS is caused by a disorder of the immune system, treatments should regulate the immune response. Sphingosylphosphorylcholine (SPC) is a sphingolipid that mediates cellular signaling. In immune cells, SPC has several immunomodulatory functions. Accordingly, this study verifies the immunomodulatory ability and therapeutic effect of SPC in SS. To understand the function of SPC in SS, we treated SPC in female NOD/ShiJcl (NOD) mice. The mice were monitored for 10 weeks, and inflammation in the salivary glands was checked. After SPC treatment, we detected the expression of regulatory B (Breg) cells in mouse splenocytes and the level of salivary secretion-related genes in human submandibular gland (HSG) cells. Salivary flow rate was maintained in the SPC-treated group compared to the vehicle-treated group, and inflammation in the salivary gland tissues was relieved by SPC. SPC treatment in mouse cells and HSG cells enhanced Breg cells and salivary secretion markers, respectively. This study revealed that SPC can be considered as a new therapeutic agent against SS.

AB - Sjögren syndrome (SS) is an autoimmune disease in which immune cells infiltrate the exocrine gland. Since SS is caused by a disorder of the immune system, treatments should regulate the immune response. Sphingosylphosphorylcholine (SPC) is a sphingolipid that mediates cellular signaling. In immune cells, SPC has several immunomodulatory functions. Accordingly, this study verifies the immunomodulatory ability and therapeutic effect of SPC in SS. To understand the function of SPC in SS, we treated SPC in female NOD/ShiJcl (NOD) mice. The mice were monitored for 10 weeks, and inflammation in the salivary glands was checked. After SPC treatment, we detected the expression of regulatory B (Breg) cells in mouse splenocytes and the level of salivary secretion-related genes in human submandibular gland (HSG) cells. Salivary flow rate was maintained in the SPC-treated group compared to the vehicle-treated group, and inflammation in the salivary gland tissues was relieved by SPC. SPC treatment in mouse cells and HSG cells enhanced Breg cells and salivary secretion markers, respectively. This study revealed that SPC can be considered as a new therapeutic agent against SS.

KW - Regulatory B cells

KW - Sjögren syndrome

KW - Sphingosylphosphorylcholine

UR - https://www.scopus.com/pages/publications/85132896767

U2 - 10.1016/j.imlet.2022.06.008

DO - 10.1016/j.imlet.2022.06.008

M3 - Article

C2 - 35732207

AN - SCOPUS:85132896767

SN - 0165-2478

VL - 248

SP - 62

EP - 69

JO - Immunology Letters

JF - Immunology Letters

ER -

Sphingosylphosphorylcholine ameliorates experimental sjögren's syndrome by regulating salivary gland inflammation and hypofunction, and regulatory B cells

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this